Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of chronic morbidity and mortality in the United States. As COPD progresses, patients develop more frequent and severe exacerbation, and have an increased rate of emergency room visits and hospitalizations, particularly in the night time and early hours of the day when lung function is lowest and steroids and bronchodilators have their smallest effects. Patients with COPD have abnormal circadian rhythm, reflected in circadian changes in the airway caliber and resistance and respiratory symptoms. However, the cellular and molecular mechanism that underlies altered circadian rhythm in lungs of patients with COPD is not understood. Circadian clock period proteins (Per) and cryptochrome (Cry) and their transcriptional activators core CLOCK and BMAL1 regulate intrinsic daily rhythm, but the role of these molecular oscillators in lung physiology and pathology in response to environmental cues is not known. Our preliminary data show the presence of circadian oscillator in mouse and human lungs and further show that this clock oscillation is disturbed by cigarette smoke (CS) and in patients with COPD. Our preliminary data further show that the acetylation of BMAL1 and Per2 is increased in bronchial epithelial cells, macrophages and lungs of mice exposed to CS, and in sputum and lung cells from COPD patients associated with reduction in the activity/level of deacetylase sirtuin 1 (SIRT1). Genetic ablation of SIRT1 leads to dampening of circadian clock associated with exaggerated lung inflammatory responses and decline in lung function, suggesting that SIRT1 plays a regulatory role in lung circadian physiology. However, the functional consequence of altered circadian rhythmicity in lungs by CS is not known. We, therefore, hypothesize that circadian proteins BMAL1 and Per2 are altered by CS via downregulation of SIRT1 leading to disruption of circadian rhythm, increased lung inflammation and steroid resistance associated with decline in lung function in mouse model of COPD/emphysema and its exacerbations. We propose the three specific aims to test this hypothesis in vitro in bronchial epithelial cells and macrophages and in vivo in mouse lungs exposed to CS. We propose to: (1) determine the molecular mechanisms by which CS exposure results in alteration of circadian proteins BMAL1 and Per 2 in human bronchial epithelial cells, macrophages and in mouse lungs;(2) determine the mechanisms whereby SIRT1 regulates BMAL1, inflammatory response and circadian periodicity by CS;and (3) determine the role of circadian proteins and SIRT1 on CS-mediated alteration in circadian periodicity, inflammation and steroid resistance in a mouse model of COPD and its exacerbations, and in patients with exacerbations of COPD. Overall, this study will understand the cellular and molecular mechanisms of peripheral circadian-coupled lung functions and identify SIRT1 as novel target for strategic chronotherapeutic manipulation of circadian proteins and reversal of steroid resistance.

Public Health Relevance

Impact on public health: COPD is the fourth leading cause of chronic morbidity and mortality in the United States, hence it is a major public health concern. Circadian regulation of COPD exacerbations is associated with worsening and rapid decline in lung function in patients with COPD where current therapies are palliative. Our research will identify the mechanisms of molecular circadian clock in lung cells regulating lung inflammation and augment the therapeutic potentials of steroids and bronchodilators by modulating circadian proteins in COPD.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL097751-04
Application #
8309876
Study Section
Special Emphasis Panel (ZHL1-CSR-N (S1))
Program Officer
Laposky, Aaron D
Project Start
2009-09-15
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2014-07-31
Support Year
4
Fiscal Year
2012
Total Cost
$477,888
Indirect Cost
$168,576
Name
University of Rochester
Department
Public Health & Prev Medicine
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Sundar, Isaac K; Nevid, Michael Z; Friedman, Alan E et al. (2014) Cigarette smoke induces distinct histone modifications in lung cells: implications for the pathogenesis of COPD and lung cancer. J Proteome Res 13:982-96
Hwang, Jae-Woong; Sundar, Isaac K; Yao, Hongwei et al. (2014) Circadian clock function is disrupted by environmental tobacco/cigarette smoke, leading to lung inflammation and injury via a SIRT1-BMAL1 pathway. FASEB J 28:176-94
Sundar, Isaac K; Yao, Hongwei; Huang, Yadi et al. (2014) Serotonin and corticosterone rhythms in mice exposed to cigarette smoke and in patients with COPD: implication for COPD-associated neuropathogenesis. PLoS One 9:e87999
Yao, Hongwei; Sundar, Isaac K; Ahmad, Tanveer et al. (2014) SIRT1 protects against cigarette smoke-induced lung oxidative stress via a FOXO3-dependent mechanism. Am J Physiol Lung Cell Mol Physiol 306:L816-28
Biswas, S; Hwang, J W; Kirkham, P A et al. (2013) Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease. Curr Med Chem 20:1496-530
Sundar, Isaac K; Yao, Hongwei; Rahman, Irfan (2013) Oxidative stress and chromatin remodeling in chronic obstructive pulmonary disease and smoking-related diseases. Antioxid Redox Signal 18:1956-71
Hwang, Jae-woong; Yao, Hongwei; Caito, Samuel et al. (2013) Redox regulation of SIRT1 in inflammation and cellular senescence. Free Radic Biol Med 61:95-110
Yao, Hongwei; Hwang, Jae-woong; Sundar, Isaac K et al. (2013) SIRT1 redresses the imbalance of tissue inhibitor of matrix metalloproteinase-1 and matrix metalloproteinase-9 in the development of mouse emphysema and human COPD. Am J Physiol Lung Cell Mol Physiol 305:L615-24
Rahman, Irfan; MacNee, William (2012) Antioxidant pharmacological therapies for COPD. Curr Opin Pharmacol 12:256-65
Rahman, Irfan (2012) Pharmacological antioxidant strategies as therapeutic interventions for COPD. Biochim Biophys Acta 1822:714-28

Showing the most recent 10 out of 29 publications